440 related articles for article (PubMed ID: 20012482)
1. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink KJ; Verheul HM
Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
[TBL] [Abstract][Full Text] [Related]
2. Targeting angiogenesis for the treatment of prostate cancer.
Antonarakis ES; Carducci MA
Expert Opin Ther Targets; 2012 Apr; 16(4):365-76. PubMed ID: 22413953
[TBL] [Abstract][Full Text] [Related]
3. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.
Voss SD; Glade-Bender J; Spunt SL; DuBois SG; Widemann BC; Park JR; Leary SE; Nelson MD; Adamson PC; Blaney SM; Weigel B
Pediatr Blood Cancer; 2015 Jan; 62(1):45-51. PubMed ID: 25257751
[TBL] [Abstract][Full Text] [Related]
4. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.
Hussain S; Mursal M; Verma G; Hasan SM; Khan MF
Eur J Pharmacol; 2024 May; 970():176484. PubMed ID: 38467235
[TBL] [Abstract][Full Text] [Related]
5. Autophagy as a mechanism for anti-angiogenic therapy resistance.
Chandra A; Rick J; Yagnik G; Aghi MK
Semin Cancer Biol; 2020 Nov; 66():75-88. PubMed ID: 31472232
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic protein kinase inhibitors.
Grant SK
Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
8. Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis.
Van Nguyen T; Hamdan D; Falgarone G; Do KH; Van Le Q; Pamoukdjian F; Bousquet G
Target Oncol; 2024 May; ():. PubMed ID: 38761350
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
Qu K; Liu T; Lin T; Zhang X; Cui R; Liu S; Meng F; Zhang J; Tai M; Wan Y; Liu C
Oncotarget; 2016 Oct; 7(41):67650-67660. PubMed ID: 27588502
[TBL] [Abstract][Full Text] [Related]
10. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.
Wu MD; Moslehi JJ; Lindner JR
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):3-10. PubMed ID: 33275447
[TBL] [Abstract][Full Text] [Related]
11. Oligosaccharides as anti-angiogenic agents.
Cole CL; Jayson GC
Expert Opin Biol Ther; 2008 Mar; 8(3):351-62. PubMed ID: 18294105
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview.
Baglini E; Chiaverini L; Tolbatov I; Taliani S; Da Settimo F; La Mendola D; Barresi E; Marzo T
Biometals; 2024 Apr; 37(2):275-288. PubMed ID: 37930483
[TBL] [Abstract][Full Text] [Related]
13. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?
Kollipara S; Chougule M; Boddu R; Bhatia A; Ahmed T
AAPS J; 2024 Jun; 26(4):66. PubMed ID: 38862853
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Cancer Biology, Pathophysiological Development and It's Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy.
Al-Ostoot FH; Salah S; Khanum SA
Cancer Invest; 2024 Jun; ():1-46. PubMed ID: 38874308
[TBL] [Abstract][Full Text] [Related]
15. Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
Brodaczewska KK; Szczylik C; Kieda C
Contemp Oncol (Pozn); 2018 Mar; 22(1A):14-22. PubMed ID: 29628789
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic peptides application in cancer therapy; a review.
Shoari A; Khodabakhsh F; Ahangari Cohan R; Salimian M; Karami E
Res Pharm Sci; 2021 Dec; 16(6):559-574. PubMed ID: 34760005
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitors: current strategies and future prospects.
Cook KM; Figg WD
CA Cancer J Clin; 2010; 60(4):222-43. PubMed ID: 20554717
[TBL] [Abstract][Full Text] [Related]
18. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
Siemann DW
Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy for cancer: an update.
Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
